This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.

# Understanding a Coin-Flip Game Can Make You a Smarter Biotech Investor

NEW YORK ( TheStreet) -- The market has been pulling back recently and biotech stocks have not been immune to the selling. Rather than focus on a single stock in this week's column, I want to write more broadly about valuation and how it relates to expected utility theory. In general, expected utility theory argues that individuals act to maximize the difference between expected benefits minus expected costs. While this seems intuitive, it highlights some interesting aspects of biotech investing.

Let me explain using an example of a simple coin-flip game in which a coin landing heads earns the player \$100 while tails returns nothing. The expected benefit of the game is \$50, calculated as the odds of heads times the payout of heads (0.5x\$100=\$50) plus the odds of tails and the payout of tails (0.5x\$0=\$0.) Obviously, this looks like a great game but it ignores the expected costs. If I am charging to play this game, how much would you pay?

If the game cost \$20, for instance, then you should certainly play as the expected utility is \$30 (expected benefits of \$50 minus the expected costs of \$20.) As long as the cost of the game is less than \$50 the player has a positive expected utility and should play. Obviously, one could generate a number of different game structures but the basic analysis is the same.

So how does this relate to biotech investing?

When investing in a clinical stage biotech company, investors are implicitly playing an analogous game. There is a probability of success (regulatory approval), expected payouts from success (discounted cash flow), probability of failure (FDA rejections), payouts from failure (additional costs), and costs for playing the game (share price.) I'm simplifying things, of course, but it's still a good heuristic approach.

Take, for instance, a biotech company that has a 50 percent chance of drug approval and the discounted cash flow on approval is expected to be \$100 per share. To keep it simple I will assume that the costs of failure (drug rejection) are \$0. Given these assumptions, the expected benefit from investing in this company is \$50 (0.5x\$100 + 0.5x\$0).
1 of 2

### Check Out Our Best Services for Investors

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

###### Product Features:
• \$2.5+ million portfolio
• Large-cap and dividend focus
##### Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

###### Product Features:
• Buy, hold, or sell recommendations for over 4,300 stocks
• Unlimited research reports on your favorite stocks
• A custom stock screener
##### Stocks Under \$10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

###### Product Features:
• Model portfolio
14-Days Free
Only \$9.95
14-Days Free

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

###### Product Features:
• Diversified model portfolio of dividend stocks
##### Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

###### Product Features:
• Model Portfolio
##### Options Profits

###### Product Features:
• Actionable options commentary and news
BIOD \$1.01 0.00%
SGEN \$47.65 0.00%
AAPL \$126.44 0.00%
FB \$87.28 0.00%
GOOG \$523.40 0.00%

#### Markets

 DOW 17,730.11 -27.8 -0.16% S&P 500 2,076.78 -0.64 -0.03% NASDAQ 5,009.2140 -3.909 -0.08%